Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDRiver EOC 302: Tuvusertib with Niraparib or Lartesertib in BRCA/HRD-positive epithelial ovarian cancer after PARP inhibitor progression
2024-511202-23-00Phase 2Completed
- Sponsor
- Merck KGaA
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 2, randomised, open-label trial in epithelial ovarian cancer (EOC) comparing Tuvusertib + Niraparib (Zejula) with Tuvusertib + Lartesertib (2 arms). Primary endpoints: Confirmed Objective Response (OR) in Part A, Confirmed Objective Response (OR) in Part B and 2 more. Started Sep 2024; status: completed.
02
Drugs
tuvusertibnirapariblartesertib
03
Conditions
epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on 2024-511202-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511202-23-00.